OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
3.260
-0.070 (-2.10%)
At close: May 29, 2025, 4:00 PM
3.250
-0.010 (-0.31%)
After-hours: May 29, 2025, 4:18 PM EDT
OncoCyte Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for OncoCyte stock ranges from a low of $4.00 to a high of $8.00. The average analyst price target of $5.42 forecasts a 66.26% increase in the stock price over the next year.
Price Target: $5.42 (+66.26%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for OncoCyte stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Maintains $5 → $8 | Strong Buy | Maintains | $5 → $8 | +145.40% | May 21, 2025 |
| Needham | Needham | Strong Buy Reiterates $4.25 | Strong Buy | Reiterates | $4.25 | +30.37% | May 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $4.25 | Strong Buy | Reiterates | $4.25 | +30.37% | Apr 8, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +53.37% | Mar 28, 2025 |
| Stephens & Co. | Stephens & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | +22.70% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
1.49M
from 1.88M
Decreased by -20.84%
Revenue Next Year
3.87M
from 1.49M
Increased by 160.04%
EPS This Year
-0.93
from -4.66
EPS Next Year
-0.91
from -0.93
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.2M | 6.4M | 13.9M |
| Avg | 1.5M | 3.9M | 13.3M |
| Low | 392,000 | 1.9M | 12.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 67.5% | 330.2% | 258.0% |
| Avg | -20.8% | 160.0% | 244.3% |
| Low | -79.2% | 25.1% | 234.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.86 | -0.79 | -0.87 |
| Avg | -0.93 | -0.91 | -0.84 |
| Low | -1.02 | -0.99 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.